Trasylol Public Health Advisory Cites Kidney, Heart Attack, Stroke Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will convene an advisory committee meeting to discuss the risks and benefits of Bayer's transfusion-sparing agent following risk reports.